Barclays
XLO icon

Barclays’s Xilio Therapeutics XLO Stock Holding History

Barclays’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.1K Buy
+115
New +$961 ﹤0.01% 4921
2022
Q2 		– Sell
-89
Closed -$8K – 5299
2022
Q1 		$8K Buy
+89
New +$14.1K ﹤0.01% 4641

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Barclays's XLO Position: Q2 2026 in Review

Barclays opened a new position in Xilio Therapeutics (XLO) in Q2 2026: 115 shares worth $1.1K. The stake represents ﹤0.01% of the portfolio and ranks #4921 among its holdings. This is a return to the name: Barclays previously reported a position in XLO as recently as Q1 2022.

Barclays first reported a position in XLO in Q1 2022 and has held it in 2 quarters since. The position peaked at $8K in Q1 2022. 26 funds tracked by Wall St. Rank hold XLO as of Q2 2026.

  • Barclays held 115 shares of Xilio Therapeutics worth $1.1K as of Q2 2026.
  • Xilio Therapeutics was a new Barclays position in Q2 2026.
  • Xilio Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4921 holding.
  • Barclays first reported a position in Xilio Therapeutics in Q1 2022 and has held it in 2 quarters since.
  • Barclays's Xilio Therapeutics position peaked at $8K in Q1 2022.
  • 26 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.